Bailard’s Oric Pharmaceuticals ORIC Stock Holding History

Bailard’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-38,505	Closed	-$123K	–	764
2022 Q3	$123K	Buy	+38,505	New	+$154K	0.01%	627

Other funds holding ORIC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Bailard's ORIC Position: Q4 2022 in Review

Bailard sold out of Oric Pharmaceuticals (ORIC) in Q4 2022, closing a stake of 38,505 shares — an estimated $123K sold.

Bailard first reported a position in ORIC in Q3 2022 and held it in 1 quarter. The position peaked at $123K in Q3 2022. 64 funds tracked by Wall St. Rank hold ORIC as of Q4 2022.

Bailard reported no remaining Oric Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Bailard sold 38,505 Oric Pharmaceuticals shares in Q4 2022, an estimated $123K.
Bailard first reported a position in Oric Pharmaceuticals in Q3 2022 and held it in 1 quarter.
Bailard's Oric Pharmaceuticals position peaked at $123K in Q3 2022.
64 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q4 2022.

Based on Bailard's 13F filing for Q4 2022, filed 2 Feb 2023.